Uncovering a New Avenue to Fight Retinal Diseases: Identifying Retinal Ganglion Cells as a Novel Signaling Pathway Through Fixational Eye Movements With Discovery of the ZNF385D Biomarker Group for AKB-9778 Therapeutic Intervention
ISEF · 2026 Translational Medical Science
Overview
Retinal degenerative diseases (RDDs) affect 300 million patients worldwide. Current imaging techniques detect RDDs in late stages after significant vision loss. Approximately 40% of Retinal Ganglion Cells (RGCs) die before structural changes are detectable on imaging, suggesting that they could serve as a novel marker of early degeneration and provide quality biomarkers. Current methods for acquiring RGC spike-trains cost more than $100,000 and are invasive, requiring ex vivo surgical implantation of electrodes into the brain. In addition, there are no known biomarkers or therapeutic solutions for RGC death. To address this, I developed the first-ever low-cost (<$150), noninvasive device using an Arducam Global Shutter and ESP32 Microcontroller that maps RGC firing rates via fixational eye movements (FEMs) and microsaccades, trained on 1,000 gaze-tracking samples. Through this pathway, I implemented a Deep SVDD model, achieving 96% prognostic accuracy 38 months earlier than SOTA imaging. To discover new biomarkers, I mapped degenerated spike-trains to RNA-seq data via manifold alignment, then performed differential gene expression analysis, and constructed Protein-Protein Interaction (PPI) networks. I found ZNF385D as a novel biomarkercausing RGC cell death. Through Magnetic-Activated Cell Sorting (MACS) and Western blotting methods, I show significant ZNF385D protein expression (p<0.001 & Log2FC > 3.5) in retinal tissue. I observed that AKB-9778 effectively inhibited ZNF385D expression via Molecular Docking (binding affinity of -9.4 kcal/mol), creating a therapeutic pathway for RDD restoration. This is the first study leveraging RGCs as a new pathway to detect and fight RDDs, and in vitro improvements could prevent vision loss for millions of patients.
Awards (1)
- First Award of $6,000 $6,000
Competition history
- ISEF 2026
Resources
Related projects
CWSF · 2026
Window to the Mind: A Multi-Stage Computational Pipeline for Early Alzheimer's Intervention
ISEF · 2026
Novel Fusion Protein Approach in Slowing Glaucoma Progression With Computational and Mathematical Modelling
ISEF · 2023
Assessing the Photoreceptor Expression in Retinal Organoids From a Patient With Rhodopsin Copy Number Variation
ISEF · 2025
In vitro and in silico Retinal Models of Neurodevelopmental Disorders
CWSF · 2026
In Silico Discovery of Pharmacological Chaperones of P23H Rhodopsin to Treat Retinitis Pigmentosa
ISEF · 2021
Treating Blindness: The Role of Autophagy in Diabetic Retinopathy
ISEF · 2020
Triangulating Fluoxetine into a Novel Macular Degeneration Therapy via Biochemical, in vivo and Big Data Approaches
ISEF · 2015
Investigation of Mechanisms of Action of FGF1 and FGF21 on the Prevention of Diabetic Retinopathy
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair